FDA Adverse Event Malfunction Summary report: N

VENTANA PD-L1 (SP142) ASSAY

MDR report key: 16206059 · Received January 19, 2023

Report

Report Number
2028492-2023-00003
Event Type
Malfunction
Date Received
January 19, 2023
Date of Event
December 23, 2022
Report Date
January 19, 2023
Manufacturer
VENTANA MEDICAL SYSTEMS INC
Product Code
PLS
PMA / PMN Number
P160002
Removal / Correction Number
2028492-11-09-2022-003-C
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

ROCHE OBSERVED UNACCEPTABLE, LIGHT STAINING WITH SOME VENTANA PD-L1 (SP142) ON-MARKET LOTS, DURING INTERNAL COMPARISON STUDIES. LIGHT STAINING AFFECTS THE BORDERLINE OF POSITIVE VERSUS NEGATIVE TEST RESULTS. AN ON-GOING INVESTIGATION HAS DETERMINED THE ROOT CAUSE IS RELATED TO VARIABILITY IN THE SELECTION OF ANTIBODY CONCENTRATION IN RAW MATERIALS, AFFECTING SPECIFIC VENTANA PD-L1 (SP142) ASSAY LOTS MADE WITH THE IMPACTED RAW MATERIALS. A NOTIFICATION HAS BEEN SENT TO US CUSTOMERS INFORMING THEM OF THE ISSUE TO IMMEDIATELY DISCONTINUE THE USE OF AND DISCARD ANY REMAINING INVENTORY OF SPECIFIC IMPACTED LOTS AND INFORMING OF AN UPDATED DATE OF EXPIRATION FOR CERTAIN LOTS. THOUGH IT IS LIKELY THAT THE REAGENT LOT USED WAS ONE OF THE IDENTIFIED LOTS IMPACTED BY THE ISSUE DESCRIBED ABOVE, THE CUSTOMER WAS UNABLE TO PROVIDE THE REAGENT LOT NUMBER THAT WAS USED FOR THE INITIAL TEST.

Description of Event or Problem · 0

A CUSTOMER FROM JAPAN ALLEGED DISCREPANT RESULTS WITH THE VENTANA PD-L1 (SP142) ASSAY. THE ALLEGED SAMPLE INITIALLY GENERATED A NEGATIVE RESULT WHICH WAS REPORTED TO THE MEDICAL PERSONNEL TREATING THE PATIENT. THE SAME TISSUE WAS THEN RETESTED AND GENERATED A POSITIVE RESULT. TO DATE, NO HARM OR INJURY IS ALLEGED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
369844 VENTANA PD-L1 (SP142) ASSAY PROGRAMMED DEATH-LIGAND 1 (PD-L1) IVD, ANTIBODY PLS VENTANA MEDICAL SYSTEMS INC NA ASKU

Patients

Seq Age Sex Outcome Treatment
1 Unknown